{"disease":{"id":"hepatic-cirrhosis","name":"hepatic cirrhosis"},"drugs":{"marketed":[{"drug_id":"chlorothiazide","indication_name":"Edema in Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"potassium-bicarbonate","indication_name":"Prevention of Potassium Depletion - Hepatic Cirrhosis with Ascites","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POTASSIUM BICARBONATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":14,"revenue":null,"mechanism":null},{"drug_id":"spironolacton","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Spironolacton","company_name":"ACS Biomarker","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chlorothiazide","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"frusemide","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Frusemide","company_name":"Melbourne Health","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"torasemide","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Torasemide","company_name":"Medical University of Warsaw","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"hydrochlorothiazide","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"spironolactone","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"spironolactone","company_name":"Generic (originally Searle/Pfizer)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"Aldosterone Antagonist [EPC]","quality_score":56,"revenue":null,"mechanism":"Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure."},{"drug_id":"bumetanide","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bumex","generic_name":"BUMETANIDE","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 1","drug_class":"Loop Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"furosemide","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lasix","generic_name":"furosemide","company_name":"Generic (originally Hoechst AG)","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2, CDGSH iron-sulfur domain-containing protein 1, G-protein coupled receptor 35","drug_class":"Loop Diuretic [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chlorthalidone","indication_name":"Edema associated with hepatic cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"spirolactone","indication_name":"Edema due to Hepatic Cirrhosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"spirolactone","company_name":"Second Xiangya Hospital of Central South University","drug_phase":"phase_1","molecular_target":"Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05140837","title":"Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Hepatopancreatobiliary Surgery Institute of Gansu Province","has_results":false},{"nct_id":"NCT05433948","title":"Diagnosing Minimal Hepatic Encephalopathy","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":550,"lead_sponsor_name":"Esbjerg Hospital - University Hospital of Southern Denmark","has_results":false},{"nct_id":"NCT03405909","title":"Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study","phase":"","overall_status":"COMPLETED","enrollment_count":517,"lead_sponsor_name":"University Hospital Erlangen","has_results":false},{"nct_id":"NCT04155515","title":"A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06355479","title":"A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":328,"lead_sponsor_name":"Healthgen Biotechnology Corp.","has_results":false},{"nct_id":"NCT05128305","title":"Integrated Traditional Chinese and Clinical Medicine for Chronic Hepatitis B and Its Complication","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":276,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT05904470","title":"A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04073290","title":"Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":238,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT01842581","title":"The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"Bausch Health Americas, Inc.","has_results":true},{"nct_id":"NCT03804593","title":"HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)","phase":"","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Epigenomics, Inc","has_results":false},{"nct_id":"NCT02372682","title":"Shear Wave Sonoelastography in Pediatric Liver Fibrosis","phase":"","overall_status":"COMPLETED","enrollment_count":171,"lead_sponsor_name":"St. Louis University","has_results":true},{"nct_id":"NCT07528690","title":"Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":162,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT03486912","title":"A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":155,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT05484206","title":"Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Vir Biotechnology, Inc.","has_results":false},{"nct_id":"NCT03593447","title":"To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT03191851","title":"Evaluation of 'Melody' Paracentesis Device for Ascites Therapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT06619106","title":"Development of a Cognitive Tool for Rapid and Reliable Screening of Minimal Hepatic Encephalopathy: Pilot Study","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04643795","title":"Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Madrigal Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05466669","title":"Prediction of Post-TIPS Hepatic Encephalopathy in Patients With Liver Cirrhosis","phase":"","overall_status":"UNKNOWN","enrollment_count":83,"lead_sponsor_name":"Johannes Gutenberg University Mainz","has_results":false},{"nct_id":"NCT06022237","title":"Efficacy and Safety of Oral Ibandronate in Patients of Liver Cirrhosis With Hepatic Osteodystrophy.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT03420768","title":"A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT04322201","title":"Continuous Passive Paracentesis for Intra-abdominal Hypertension","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Centro Hospitalar de Lisboa Central","has_results":false},{"nct_id":"NCT03712280","title":"MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Mallinckrodt","has_results":true},{"nct_id":"NCT05835180","title":"A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Sagimet Biosciences Inc.","has_results":false},{"nct_id":"NCT03493204","title":"Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT04787276","title":"Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy","phase":"NA","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Bogomolets National Medical University","has_results":false},{"nct_id":"NCT06750276","title":"A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05999773","title":"SGLT-2 Inhibitors in the Treatment of Ascites","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Palermo","has_results":false},{"nct_id":"NCT04682847","title":"Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","has_results":false},{"nct_id":"NCT06664307","title":"Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Hospital Universitario Virgen Macarena","has_results":false},{"nct_id":"NCT04082780","title":"Rifamycin in Minimal Hepatic Encephalopathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Hunter Holmes Mcguire Veteran Affairs Medical Center","has_results":false},{"nct_id":"NCT06224023","title":"Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Carol Davila University of Medicine and Pharmacy","has_results":false},{"nct_id":"NCT03445208","title":"A Study of Experimental Medication BMS-986036 Given to Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05045482","title":"Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Zydus Therapeutics Inc.","has_results":false},{"nct_id":"NCT03152188","title":"Oral Fecal Transplant in Cirrhosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT07069725","title":"The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06425380","title":"Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy","phase":"NA","overall_status":"RECRUITING","enrollment_count":11,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04771104","title":"The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver Cirrhosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03082937","title":"An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Albireo","has_results":false},{"nct_id":"NCT04155099","title":"Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Ochsner Health System","has_results":false},{"nct_id":"NCT06987968","title":"A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Genfit","has_results":false},{"nct_id":"NCT06245473","title":"Metobolomics in the Characterisation of HE","phase":"","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04664621","title":"HepQuant to Predict Hepatic Encephalopathy After TIPS","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Northwestern University","has_results":false}],"total":43},"guidelines":[],"source":"Drug Landscape verified database"}